Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

November 19, 2025
The Pharmidex team will be in London for London Life Sciences Week from the 16th. Janette Dalay Robertson and Ash Alavijeh will be attending a range of events across the week. We are looking forward to a busy week discussing all things life-science related. Get in touch if you’d like to meet with us during the week as we visit existing clients and stakeholders!
November 12, 2025
Our Head of Integrated Therapeutics and CNS, Dr. Stephen Mitchell , our Business Development Manager, Janette Dalay Robertson and our Senior Research Scientist in CNS, Jewel Ahmed will be there to engage with attendees, share insights and explore new collaborations driving innovation in Parkinson’s disease drug discovery and development. If you’re attending, don’t hesitate to reach out, they’ll be delighted to connect and discuss how Pharmidex’s integrated expertise can help move your research from concept to clinic.
November 11, 2025
We are delighted to share that Prof. Mo Alavijeh will be attending the upcoming 🔬 OBN (UK) Ltd BioTuesday: A Spotlight on the Latest R&D for the Diagnosis & Treatment of Prostate Cancer 📅 11 November 2025 📍 Ipsen, Paddington, London This event brings together leading experts and innovators shaping the future of prostate cancer research and therapy. If you’re attending, don’t miss the opportunity to meet with Prof. Mo Alavijeh (FRSC, FRSM), and explore how collaboration can accelerate progress in drug discovery and development.
More Posts